News & Updates
Showing Oncology articles
Showing
Immunotherapy, TACE-based regimen may reshape HCC treatment landscape
In the EMERALD-1 trial, durvalumab plus bevacizumab (D+B) combined with transarterial chemoembolization (TACE) improved progression-free survival (PFS) in individuals with unresectable hepatocellular carcinoma (HCC) eligible for embolization.
Folic acid may induce toxicities in capecitabine-treated CRC patients
The presence of folic acid in plasma and intake of folic acid supplements appear to contribute to chemotherapy-induced toxicities in patients treated with capecitabine for colorectal cancer (CRC), reports a recent study.
Does radiotherapy improve survival in NSCLC patients with cachexia?
Palliative-intent radiation was performed more frequently in patients with advanced nonsmall-cell lung cancer (NSCLC) and cachexia than those without weight loss. Unfortunately, tumour-directed therapy, whether in a curative or a palliative approach, proves inadequate in improving cachexia patient survival across all stages of the disease.
Sitra + nivo slightly better than docetaxel in advanced NSCLC
Treatment with sitravatinib plus nivolumab (sitra + nivo) results in numerically longer median overall survival (OS), albeit statistically nonsignificant, in patients with advanced nonsquamous nonsmall-cell lung cancer (NSCLC) compared with docetaxel, a study has shown.
Sacituzumab govitecan makes case as third-line therapy in mTNBC
Third-line treatment with sacituzumab govitecan works better than the physician’s treatment of choice in metastatic triple-negative breast cancer (mTNBC), an invasive histologic subtype with a poor prognosis and rapid progression, as shown in a recent study.
Erdafitinib prevents recurrence in high-risk NMIBC
Recurrence-free survival (RFS) is significantly longer with erdafitinib treatment than with intravesical chemotherapy in patients with papillary-only, high-risk nonmuscle-invasive bladder cancer (NMIBC) who had disease recurrence after bacillus Calmette–Guérin (BCG) therapy and were ineligible for radical cystectomy, according to a study.